Zynex, Inc. (NASDAQ:ZYXI) CEO Sells $17,840.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $8.92, for a total transaction of $17,840.00. Following the completion of the sale, the chief executive officer now owns 14,625,350 shares in the company, valued at approximately $130,458,122. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total transaction of $17,260.00.

Zynex Stock Up 1.5 %

ZYXI opened at $8.76 on Monday. Zynex, Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The firm’s fifty day moving average price is $8.11 and its two-hundred day moving average price is $9.04. The company has a market capitalization of $278.97 million, a P/E ratio of 58.40 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business’s revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 earnings per share. On average, analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current year.

Analyst Upgrades and Downgrades

ZYXI has been the topic of a number of recent research reports. Royal Bank of Canada decreased their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. HC Wainwright lifted their price target on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ZYXI. Millennium Management LLC lifted its holdings in shares of Zynex by 66.5% during the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after acquiring an additional 118,615 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Zynex by 68.7% during the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after acquiring an additional 77,300 shares during the period. LSV Asset Management lifted its holdings in shares of Zynex by 45.1% during the first quarter. LSV Asset Management now owns 108,935 shares of the company’s stock valued at $1,348,000 after acquiring an additional 33,840 shares during the period. Janney Montgomery Scott LLC lifted its holdings in shares of Zynex by 22.3% during the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock valued at $1,179,000 after acquiring an additional 26,368 shares during the period. Finally, WINTON GROUP Ltd lifted its holdings in shares of Zynex by 147.6% during the second quarter. WINTON GROUP Ltd now owns 36,841 shares of the company’s stock valued at $343,000 after acquiring an additional 21,960 shares during the period. 29.68% of the stock is owned by institutional investors.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.